NextCure (NASDAQ:NXTC) Upgraded to “Hold” at Wall Street Zen

NextCure (NASDAQ:NXTC) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also commented on NXTC. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. LADENBURG THALM/SH SH upgraded shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, November 7th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $23.00.

NextCure Price Performance

NextCure stock opened at $11.14 on Friday. NextCure has a one year low of $2.69 and a one year high of $15.74. The company’s fifty day moving average price is $10.26 and its two-hundred day moving average price is $7.12. The company has a market capitalization of $29.86 million, a price-to-earnings ratio of -0.46 and a beta of 1.54.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.06) by $0.84. As a group, sell-side analysts anticipate that NextCure will post -1.87 earnings per share for the current year.

Institutional Investors Weigh In On NextCure

A hedge fund recently raised its stake in NextCure stock. Cable Car Capital LP boosted its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the quarter. Cable Car Capital LP owned 28.29% of NextCure worth $349,000 at the end of the most recent quarter. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.